Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease

被引:87
作者
Murawaki, Y [1 ]
Ikuta, Y [1 ]
Idobe, Y [1 ]
Kitamura, Y [1 ]
Kawasaki, H [1 ]
机构
[1] TOTTORI UNIV,SCH MED,DEPT PATHOL 2,YONAGO,TOTTORI 683,JAPAN
关键词
liver disease; TIMP-1;
D O I
10.1016/S0168-8278(97)80454-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Tissue inhibitor of metalloproteinase (TIMP)-1 is an important regulator of matrix metalloproteinase activity. To clarify the changes in TIMP-1 in diseased livers, we measured TIMP-1 concentrations in liver tissue samples from patients with chronic liver disease, The relationship between serum and liver levels of TIMP-1 was also examined in some patients. Methods: The subjects were 68 patients who underwent liver biopsy The liver TIMP-1 concentration was measured using an enzyme immunoassay after the extraction of TIMP-1 with 2 M guanidine. Results: As compared with the controls (n = 10), the liver TIMP-1 level was increased 2.2-fold in the 24 chronic active hepatitis 2A patients, 2.9-fold in the 10 chronic active hepatitis 2B patients and 4.1-fold in the six liver cirrhosis patients, but no significant increase was observed among the 18 chronic persistent hepatitis patients, The liver TIMP-1 levels mere closely correlated with the histological degrees of periportal necrosis, portal inflammation, and liver fibrosis, When the localization of TIMP-1 was examined immunohistochemically, TIMP-1 was stained mainly in hepatocytes, and the intensity was stronger in the livers of chronic active hepatitis and liver cirrhosis patients than in those of the chronic persistent hepatitis patients, The serum TIMP-1 and liver TIMP-1 levels were significantly correlated, indicating that serum TIMP-1 could reflect the change of liver TIMP-1 in patients with chronic liver disease. Conclusion: Liver TIMP-1 concentration increases with progression of the liver disease, when the degradation of extracellular matrix proteins is decreased, resulting in the development of liver fibrosis.
引用
收藏
页码:1213 / 1219
页数:7
相关论文
共 34 条
[1]   INCREASED TRANSFORMING GROWTH FACTOR-BETA-1 GENE-EXPRESSION IN HUMAN LIVER-DISEASE [J].
ANNONI, G ;
WEINER, FR ;
ZERN, MA .
JOURNAL OF HEPATOLOGY, 1992, 14 (2-3) :259-264
[2]   HIGH METALLOPROTEINASE INHIBITOR CONTENT OF HUMAN CIRRHOSIS AND ITS POSSIBLE CONFERENCE OF METASTASIS RESISTANCE [J].
BARSKY, SH ;
GOPALAKRISHNA, R .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (02) :102-108
[3]   Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver [J].
Benyon, RC ;
Iredale, JP ;
Goddard, S ;
Winwood, PJ ;
Arthur, MJP .
GASTROENTEROLOGY, 1996, 110 (03) :821-831
[4]   TRANSFORMING GROWTH FACTOR-BETA-1 AND FACTOR-ALPHA IN CHRONIC LIVER-DISEASE - EFFECTS OF INTERFERON ALFA THERAPY [J].
CASTILLA, A ;
PRIETO, J ;
FAUSTO, N .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (14) :933-940
[5]  
Cawston T.E., 1986, PROTEINASE INHIBITOR, P589
[6]   TUMOR-NECROSIS-FACTOR-ALPHA INDUCES MESSENGER-RNA FOR COLLAGENASE AND TIMP IN HUMAN SKIN FIBROBLASTS [J].
CHUA, CC ;
CHUA, BHL .
CONNECTIVE TISSUE RESEARCH, 1990, 25 (02) :161-170
[7]   EVIDENCE FOR METALLOPROTEINASE AND METALLOPROTEINASE INHIBITOR IMBALANCE IN HUMAN OSTEOARTHRITIC CARTILAGE [J].
DEAN, DD ;
MARTELPELLETIER, J ;
PELLETIER, JP ;
HOWELL, DS ;
WOESSNER, JF .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (02) :678-685
[8]  
DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629
[9]  
GROOTE J, 1968, LANCET, V2, P621
[10]   HUMAN HEPATIC LIPOCYTES SYNTHESIZE TISSUE INHIBITOR OF METALLOPROTEINASES-1 - IMPLICATIONS FOR REGULATION OF MATRIX DEGRADATION IN LIVER [J].
IREDALE, JP ;
MURPHY, G ;
HEMBRY, RM ;
FRIEDMAN, SL ;
ARTHUR, MJP .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (01) :282-287